DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,613,807 B2 Uhrich (45) Date of Patent: *Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,613,807 B2 Uhrich (45) Date of Patent: *Sep USOO6613807B2 (12) United States Patent (10) Patent No.: US 6,613,807 B2 Uhrich (45) Date of Patent: *Sep. 2, 2003 (54) THERAPEUTIC POLYANHYDRIDE DE 288387 3/1991 ........... CO8G/67/04 COMPOUNDS FOR DRUG DELIVERY EP O246341 11/1987 ........... A61 L/27/00 EP O 246 341 * 11/1987 (75) Inventor: Kathryn E. Uhrich, Hoboken, NJ (US) NL 9000237 8/1991 .......... A61 K/31/60 WO WO 90/09779 9/1990 ............ A61K/7/16 WO 91/O9831 * 7/1991 (73) ASSignee: ST'State tly, New W. WO-91/09831 7/1991 ......... CO7C/69/035 ersey, New Brunswick, NJ (US) WO WO-97/39738 10/1997 ... A61 K/9/16 (*) Notice: Subject to any disclaimer, the term of this W Wo: to r : patent is extended or adjusted under 35 WO 99/12990 * 3/1999 U.S.C. 154(b) by 0 days. WO WO-99/29885 6/1999 ............. C12P/1/OO This patent is Subject to a terminal dis OTHER PUBLICATIONS claimer. Anastasiou, T.J. "Novel Polyanhydrides with Enhanced Thermal and Solubility Properties”, Macromolecules, 33 (21) Appl. No.: 09/917,231 (17), (2000).pp, 6217–6221. Anastasiou, T.J. "Novel, Degradable Polyanhydrides”, (22) Filed: Jul. 27, 2001 25th Annual Meeting Transactions of the Society for Bio (65) Prior Publication Data materials, Abstract,(1999).p, 79, Anastasiou, T.J. "Synthesis of Novel, Degradable Polyan US 2002/0098161 A1 Jul. 25, 2002 hydrides Containing Para-AminoSalicylic Acid as Drug Delivery Devices for Tuberculosis Treatment', Polymer Related U.S. Application Data Preprints, 41(2), (Aug. 2000),pp. 1366–1367. Attawia, M.A. "Biocompatibility Testing of Poly(anhy (63) Continuation-in-part of application No. 09/627.215, filed on dride-co-imides) Containing Pyromellitylimidoalanine”, Jul. 27, 2000. The 21st Annual Meeting of the Society for Biomaterials, (51) Int. Cl....................... A61K 47/32; A61K 31/195; Abstract.(1994).p. 222. A61K 31/43; A61K 31/74 Attawia, M.A. "Cytotoxicity testing of poly(anhydride (52) U.S. Cl. .................... 514/772.5; 514/197; 514/201; co-imides) for Orthopedic applications”, Journal of Bio 514/567; 424/78.08 medical Materials Research, 29, (1995),pp. 1233-1240. (58) Field of Search .............................. 514/772.5, 197, Attawia, M.A. “In Vitro Bone Biocompatibility of Poly 514/201,567; 424/428, 427, 78.08, 409, (anhydride-co-imides) Containing Pyromellitylimidoala 420 nine”, Journal of Orthopedic Research, 14, (1996),pp. 445-454. (56) References Cited Attawia, M.A. "Proliferation, Morphology, and Protein Expression by Osteoblasts Cultured on Poly(anhydrideco-a- U.S. PATENT DOCUMENTS mides)”, J. Biomed. Mater. Res. (Appl. Biomater), 48, 4,062.855 A 12/1977 Allan et al. ............ 260/295 PA (1999), pp. 322–327. 4,126,445. A 11/1978 Allan et al. .................... 71/94 Attawia, M.A., “Regional drug delivery with radiation for 4,684,620 A 8/1987 Hruby et al. ................. 514/11 the treatment of Ewing's Sarcoma-In Vitro development of 4,757,128 A 7/1988 Domb et al. ... ... 528/271 a taxol release system”, Journal of Controlled Release, 71, 4,792.598 A 12/1988 Ziegast ......... ... 528/2O6 (2001),pp. 193–202. 4,857,311 A 8/1989 Domb et al. .................. 424/78 Attawia, M.A. “The Long Term Osteoblast Response to 4,868.274 A 9/1989 Gupta et al. ................ 528/206 Poly(anhydride-co-imides); A New Degradable Polymer 4,886.870 A 12/1989 D’Amore et al. ........... 528/206 4,888,176. A 12/1989 Langer et al. .... ... 424/426 for Use in Bone", Proc. of the Fifth World Biomaterials 4,891.225 A * 1/1990 Langer et al. ... ... 424/428 Congress, Toronto, Canada, (1996).p. 113. 4,906,474 A 3/1990 Langer et al. ... 424/428 (List continued on next page.) 4,938,949 A 7/1990 Borch et al. .................. 424/10 4997,904 A 3/1991 Domb .......... ... 528/2O6 Primary Examiner Thurman K. Page 4,999,417 A 3/1991 Domb .......... ... 528/271 Assistant Examiner Blessing Fubara 5,082,925 A 1/1992 Shalaby et al. ... 528/354 (74) Attorney, Agent, or Firm-Schwegman, Lundberg, 5,175.235 A 12/1992 Domb et al....... ... 528/271 Woessner & Kluth, PA. 5,259,968 A 11/1993 Emert et al. ... ... 252/51.5 A 5,264,540 A 11/1993 Cooper et al. ... 528/272 (57) ABSTRACT 5,498,729 A 3/1996 Domb .......... ... 548/500 5,514,764 A 5/1996 Frechet et al. ................ 528/10 Polyanhydrides which link low molecular weight drugs 5,545.409 A 8/1996 Laurencin et al. .......... 424/426 containing a carboxylic acid group and an amine, thiol, 5,629,009 A 5/1997 Laurencin et al. .......... 424/426 alcohol or phenol group within their structure into polymeric drug delivery Systems are provided. Also provided are 5,902,110 A 5/1999 Alfano et al. ..... ... 433/215 5,902,599 A 5/1999 Anseth et al. ... 424/426 methods of producing polymeric drug delivery Systems via 5,942.252 A 8/1999 Tice et al. ..... ... 424/501 these polyanhydride linkers as well as methods of adminis 6,071,530 A 6/2000 Polson et al. ............... 424/426 tering low molecular weight drugs to a host via the poly FOREIGN PATENT DOCUMENTS meric drug delivery Systems. DE 2883.11 3/1991 .......... AO1 N/25/10 33 Claims, No Drawings US 6,613,807 B2 Page 2 OTHER PUBLICATIONS Gouin, S.,et al. "New Polyanhydrides Made from a Bile Acid Dimer and Sebacic Acid: Synthesis, Characterization, Beaton, M.L. "Synthesis of a novel poly(anhy and Degradation”, Macrmolecules, 33, (2000),pp. dride-ester)”, The Rutgers Scholar. An Electronic Bulletin of Undergraduate Research, 3, www.rutgerSScholarrut 5379-5383. gers.edu/volume03/beatuhri/beatuhri.html.(2001), 7 pgs. Ibim. S.“Controlled Release Based on Poly(anhydride Bedell, C.,"Processing and Hydrolytic Degradation of Aro co-imides)”, Proc. Intern. Symp. Control. Rel. Bioact. matic, Ortho-Substituted Polyanhydrides”, Journal of Mater, 22, (1995).2 pgs. Applied Polymer Science, 80, (2001), pp. 32–38. Ibim, S.M. "Poly(anhydride-co-imides): In Vivo Biocom Campo, C.J., “Polyanhydrides: the effects of ring substitu patibility in a rat model”, Biomaterials, 19, (1998),pp. tion changes on polymer properties”, Polymer Bulletin, 42, 941-951. (1999), pp. 61-68. Ibim, S.E. "Preliminary In Vivo Report on the Osteocom Chafi, N.," Dosage Form with Salicylic Acid Attached to the patibility of Poly(anhydride-co-imides) evaluated in a Polyanhydride Polymer Dispersed in an Eudragit Matrix”, Tibial Model”, App. Biomater, 43(4), (1998),pp. 374–379. International Journal of Pharmaceutics, 52, (1989),pp. Krogh-Jespersen, E.,"Synthesis of a Novel Aromatic Poly 203-211 anhydride Containing Aminosalicylic Acid', Polymer Pre Conix, A..." Aromatic Polyanhydrides, a New Class of High prints, 41 (1), (2000), pp. 1048–1049. Melting Fiber-Forming Polymers”,Journal of Polymer Sci Langer, R..."New Methods of Drug Delivery”, Science, 249, ence, XXIX, (1958), pp. 343-353. (Sep.1990).pp. 1527–1533. Conix, A..."New High-Melting Fibre-Forming Polymers', Laurencin, C.T. "Poly(andrides-co-imides): In Vivo Bio Die Makromolekulare Chemie, XXIV, (1957), pp. 76–78. compatibility Study', 23rd Annual Meeting of the Society Conix, A..."Poly 1,3-bis(p-carboxyphenoxy)-Propane for Biomaterials, New Orleans, LA, (1997), p. 483. anhydride', Macromolecular Synthesis, 2, (1996),pp. Laurencin, C.T. "The Biocompatibility of Poly(anhydride 95-99. co-imides): High Strength Polymers for Controlled Drug Domb, A.J. "Synthesis and Characterization of Biodegrad Delivery”, Proc. 24th Int'l Symp. Control. Rel. Bioact. able Aromatic Anhydride Copolymers’, Macromolecules, 25, (1992),pp. 12–17. Mater, (1997)pp. 973–974. Dukovic, G..."Novel degradable poly(anhydride-esters) for Laurencin, C.T. "The Bone Biocompatibility of Poly(anhy controlled drug release”, The Rutgers Scholar An Elec dride-co-imides)-A new generation degradable Polymer tronic Bulletin of Undergraduate Research, 1, http://rut for Orthopedic Applications”, 41st Annual Meeting of the gersscholarrutgers.edu/colume(01/uhridukofuhriduko.html, Orthopedic Research Society, Orlando, FL, (1995),pp. (1999), 10 pgs. 143-24. Erdman, L.,et al., “Polymer Prodrugs with Pharmaceuti Laurencin, C.T. "The Controlled Delivery of Radiosensi cally Active Degradation Products”, Polymer Preprints, tizers: Taxol Treatment of Ewing Sarcoma, Proc. of the 38(2), (1997)pp. 570–571. 25th Int'l Symp. Control. Rel. Bioact. Mater, (1998),pp. Erdmann, L.,"Chapter 5: Polymeric Prodrugs: Novel Poly 236-237. mers with Bioactive Components”, In, Tailored Polymeric Macedo, B.,et al. "The in vivo Response to a Bioactive Materials for Controlled Delivery Systems, I. McCulloch, et Biodegadable Polymer”, Journal of Dental Research, 78, al., (Editors), ACS Symposium Series 709, American Abstract No. 2827.(1999).p.459. Chemical Society: Washington, D.C..(1998),pp. 83-91. Macedo, B., "the In Vivo Response to Bioactive Polyanhy Erdmann, L., “Degradable poly(anhydride ester) implants: dride Monofilament”, Journal of Dental Research, 79 effects of localized Salicylic acid release on bone', Bioma (Abstract No. 3872), (2000).p. 627. terials, 21, (2000), pp. 2507-2512. Pinther, P.,"Synthesis of Polyanhydrides Containing Ester Erdmann, L., “Polymeric Prodrugs: Novel Polymers for Groups', Makromol. Chem., Rapid Commun., 11, (1990),pp. Delivery of Salicylic Acid', Annals of Biomedical Engineer 403-408. ing, 26 (Suppl. 1), Abstract No. PB.26, Annual Fall Meeting, Seidel, J.O. "Erosion of Poly(anhydride-co-imides): A Pre (1998).p. S-124. liminary Mechanistic Study”, J. Appl. Polym. Sci., 62(8), Erdmann, L., “Polymeric Salicylic Acid: In Vitro and In Vivo Degradation”, Polymer Preprints, 39(2), (1998).p. (1996), pp. 1277–1283. 224-225. Shen, E., "Morphological Characterization of Erodible Poly Erdmann, L.,"Synthesis and Characterization of a Poly mer Carriers for Drug Release', Proc. 26th Int'l Symp. meric Prodrug”, Proceedings of the American Chemical Control. Rel.
Load more

Recommended publications
  • Jeanyoung; 617 Fairchild Center, 1212 Amsterdam Av¬ A61K 31/01 (2006.01) A61K 31/375 (2006.01) Enue, New York, NY 10027 (US)
    ) ( International Patent Classification: Jeanyoung; 617 Fairchild Center, 1212 Amsterdam Av¬ A61K 31/01 (2006.01) A61K 31/375 (2006.01) enue, New York, NY 10027 (US). A61K 31/04 2006.01) A61K 33/26 (2006.01) (74) Agent: DAVITZ, Michael, A. etal.; Leason Ellis LLP, One A61K 31/015 (2006.01) A61K 33/40 2006.01) Barker Avenue, Fifth Floor, White Plains, NY 10601 (US). A61K 31/19 (2006.01) A61K 39/104 2006.01) A61K 31/197 2006.01) A61K 45/06 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/198 (2006.01) kind of national protection av ailable) . AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2019/017233 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 08 February 2019 (08.02.2019) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/628,643 09 February 2018 (09.02.2018) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available) .
    [Show full text]
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • Ultraviolet-Visible Reference Spectra C
    1536 Ultraviolet-visible Reference Spectra JP XV Butropium Bromide 1 A solution in methanol (1 in 100,000) Butropium Bromide 2 A solution in methanol (1 in 5000) Calcium Folinate An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1537 Camostat Mesilate An aqueous solution (1 in 100,000) Carbamazepine The sample solution obtained in the Assay Carbazochrome Sodium Sulfonate Hydrate An aqueous solution (1 in 100,000) 1538 Ultraviolet-visible Reference Spectra JP XV Carbidopa Hydrate A solution prepared as follows: Dissolve 0.01 g in 250 mL of a solution of hydrochloric acid in methanol (9 in 1000) Carmofur A solution in a mixture of methanol and phosphoric acid-acetic acid-boric acid buffer solution, pH 2.0 (9:1) (1 in 100,000) Carteolol Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1539 Carumonam Sodium An aqueous solution (3 in 100,000) Cefaclor An aqueous solution (1 in 50,000) Cefadroxil An aqueous solution (1 in 50,000) 1540 Ultraviolet-visible Reference Spectra JP XV Cefalexin An aqueous solution (3 in 100,000) Cefalotin Sodium An aqueous solution (1 in 50,000) Cefapirin Sodium An aqueous solution (3 in 200,000) JP XV Ultraviolet-visible Reference Spectra 1541 Cefatrizine Propylene Glycolate An aqueous solution (1 in 50,000) Cefazolin Sodium An aqueous solution (1 in 50,000) Cefbuperazone Sodium An aqueous solution (1 in 50,000) 1542 Ultraviolet-visible Reference Spectra JP XV Cefditoren Pivoxil A solution in methanol (1 in 50,000) Cefixime A solution in 0.1
    [Show full text]
  • 00246-2019.Supptables
    1 Table S1. List of ICD-10 codes identifying comorbidities during hospitalization for COPD exacerbation COPD J41, J42, J43, J440, J441, J449 COPD exacerbation J10, J11, J13, J14, J15, J16, J18, J20, J21, J22, J46, J170, J171, J178, J440, J441, J851, J12, A481, B012, B052, B250 Bacterial pneumonia J100, J110, J12, J13, J14, J15, J16, J170, J178, J18, J851, A481 Lung cancer C34 Other malignancy C00-26, C30-33, C37-41, C43-58, C60-76 Diabetes/abnormal glucose tolerance E10-14, R703 Bone fracture/osteoporosis M80-84 Interstitial pneumonia B221, J701, J704, J841, J848, J849, J990, J991, M321, M330, M331, M332, M351 Bronchial asthma J45, J46 Bronchiectasis J40, J41, J42, J47 Pulmonary thromboembolism I26 Mycobacterium infection A150-154, A156-159, A161-162, A165, A168-169, A19, A310, A319 Mycotic infection A420, A43, B37, B380-382, B390-392, B400-402, B410, B420, B440, B441, B449, B460, J172 Cor pulmonare I27 Congestive heart failure E059, I46, I50, I099, I110 Ischemic heart disease I20-25 Tachycardia I47-49, R000, T818 Autoimmune disease M05, M06, M08, M30-35 Stroke I60-64 Liver dysfunction B89, B181, B182, B659, B661, K702, K703, K72, K74, K761, K762, K763, K766, K767 Renal failure E102, E112, E142, I120, N17-19 GERD K21 Constipation or ileus K56, K590 Prostate hypertrophy N40 Abbreviations: COPD, chronic obstructive pulmonary disease; GERD, gastro-esophageal reflux disease 2 Table S2. List of baseline characteristics, comorbidities, and treatments before and during hospitalization for COPD exacerbation Baseline characteristics Sex, fiscal
    [Show full text]
  • Breeding Laboratories (Hino, Japan)
    VOL. XLII NO. 6 THE JOURNAL OF ANTIBIOTICS 989 STIMULATORY EFFECT OF CEFODIZIME ON MACROPHAGE- MEDIATED PHAGOCYTOSIS Kazunori Oishi, Keizo Matsumoto, Masashi Yamamoto, Toshihiro Morito and Toshiaki Yoshida Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 12-4 Sakamoto-machi, Nagasaki 852, Japan (Received for publication January 27, 1989) Weevaluated the ingestion of anti-sheep erythrocyte (anti-E) IgG- and IgM-coated sheep erythiocytes by murineperitoneal macrophagesexposed to cefodizime, a newsemisynthetic cephalosporin, and other antibiotics. Cefodizime enhanced the ingestion of anti-E IgG- coated erythrocytes by peritoneal macrophages from CD-I and BALB/cmice in a dose- dependent manner, but had no effect on uncoated or IgM-coated erythrocytes. Similar enhancement was observed only in the case of cefpimizole (AC-1370), among the other anti- biotics examined. These results suggest that the favorable in vivo activity of cefodizime and cefpimizole may result from their phagocytosis-enhancing as well as antimicrobial properties. The new semisynthetic cephalosporin, cefodizime, is characterized by a cephem ring which con- tains a ^w-methoxyimino-aminothiazolyl group at the 7-position and a thiazolylthio-methyl group at the 3-position. The latter substitution is thought to provide metabolic stability and a prolonged half-life in humanserum0. The efficacy of cefodizime in experimental murine infections is apparently superior to that predicted from in vitro activity2>3). Wepostulated that the enhanced in vivo activity of cefodizime may be due to drug-induced immunostimulation. This speculation was in part based upon the previous demonstration that a variety of agents, including lysophosphatidylcholine4) and fibronectin5), enhance receptor-dependent phagocytosis. Moreover, it was previously reported that cefpimizole (AC-1370), another semisynthetic cephalosporin, potentiated phagocyte function of macrophages and neutrophils6).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • CP-70429, a New Penem Antibiotic
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1547-1551 Vol. 37, No. 7 0066-4804/93/071547-05$02.00/0 Copyright © 1993, American Society for Microbiology In Vitro Antibacterial Activity and ,-Lactamase Stability of CP-70,429, a New Penem Antibiotic MASASHI MINAMIMURA, YUMI TANIYAMA, EIKO INOUE,* AND SUSUMU MITSUHASHI Episome Institute, 2220 Kogure, Fujimi-mura, Seta-gun, Gunma, Japan Received 14 January 1993/Accepted 15 April 1993 In in vitro susceptibility tests, the new penem CP-70,429 showed potent antibacterial activity against gram-positive and gram-negative bacteria except Pseudomonas aeruginosa and Xanthomonas maltophilia. CP-70,429 was stable to various types of 13-lactamases except for the enzyme from X. maltophilia and was 16- to 128-fold more active than the other compounds against 13-lactamase-producing strains of Enterobacter cloacae and Citrobacterfreundii. In the past several years, many 1-lactam antibiotics with cus aureus, like the other agents against which CP-70,429 broad antibacterial activities have undergone clinical trials. was compared. CP-70,429 showed potent activity against The penem antibiotics FCE22101 and SY5555 have broad streptococci, as did the other compounds tested. Against antimicrobial spectra and high levels of stability to ,B-lacta- Enterococcus faecalis, CP-70,429 was 4- to 16-fold more mases (4, 9). The in vitro activity of CP-65,207 was previ- active than the cephems tested, on the basis of the MIC90s. ously reported by Gootz et al. (3); CP-65,207 is a mixture of CP-70,429 was the most active compound against Esche- stereoisomers of the optically pure CP-70,429.
    [Show full text]